However, the above-mentioned possible effects of these drugs (i.e., inhibition of the pro-inflammatory RAS and enhancement of the anti-inflammatory RAS) also may imply an increase in the expression of the virus entry receptor (ACE2), leading to a particular complex situation in the case of COVID-19. The gene discussed is ACE2; the disease is COVID-19.